Document is current

Any future updates will be listed below

Efficacy and Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3 Randomized Controlled BOOST Trials

Crossref DOI link: https://doi.org/10.1007/s13300-018-0531-0

Published Online: 2018-11-24

Published Print: 2019-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark